

SHORT COMMUNICATION

DRUG - INDUCED HYPERALKALINEPHOSPHATASEMIA, A ONE YEAR RETROSPECTIVE STUDY IN KING CHULALONGKORN MEMORIAL HOSPITAL

Viroj Wiwanitkit, M.D.

Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

ABSTRACT

An increase in serum alkaline phosphatase (ALP) level is frequently associated with a variety of diseases. Such disorders as extrahepatic bile obstruction, intrahepatic cholestasis, infiltrative liver disease, hepatitis and drug induced disorder are mentioned. This study was done in order to determine the prevalence of drug induced markedly elevated serum ALP among Thai hospitalized patients. A review was made of medical records of inpatients with high ALP levels above 1,000 IU/L in King Chulalongkorn Memorial Hospital, Thailand from January 1998 to December 1998. During the one-year period, a total of 203 hospitalized patients with serum ALP levels over 1,000 IU/L were identified. Of these 203 cases, 163 had got the definitive diagnosis. In interest, only 3 cases with diagnosis of drug induced hyperalkalinephosphatasemia were identified (allopurinol in 2 cases and diphenylhydantoin in 1 case). The average serum ALP in these cases was equal to $4,023.0 \pm 3,493.6$ IU/L. Drug induced toxicity is a rare cause of hyperalkalinephosphatasemia in the hospitalized patients. The relative percentage of drug-induced hyperalkalinephosphatasemia was equal to 1.47 %. Comparing to the total ALP tests performed in the setting in the study period, the low prevalence as 1: 10,000 was observed. Nevertheless, each case of drug-induced hyperalkalinephosphatasemia seems to be severe and can be overlooked.

Key words : hyperalkalinephosphatasemia, drug-induced, Thai patients

ภาวะเอนไซม์อัลคาไลน์ฟอสฟາเตสในเลือดสูงจากยา การศึกษาข้อมูล ในช่วงเวลา 1 ปี ณ โรงพยาบาลจุฬาลงกรณ์

วีโรจน์ ไวนิชกิจ

ภาควิชาเวชศาสตร์ชั้นสูตร คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย กรุงเทพมหานคร 10330

บทคัดย่อ

ภาวะเอนไซม์อัลคาไลน์ฟอสฟາเตสในเลือดสูงเกิดได้จากหลายสาเหตุ เช่น การอุดตันของท่อน้ำดีนอกตับ และในตับ โรคของเนื้อตับ ตับอักเสบ รวมถึงตับถูกทำลายจากยา ได้ทำการศึกษา นี้เพื่อหาความชุกของภาวะเอนไซม์อัลคาไลน์ฟอสฟາเตสในเลือดสูงจากยาในกลุ่มผู้ป่วยชาวไทย โดยการทบทวนเวชระเบียนของผู้ป่วยในโรงพยาบาลจุฬาลงกรณ์ที่มีผลการตรวจพับระดับเอนไซม์อัลคาไลน์ฟอสฟາเตสในเลือดสูงกว่า 1,000 IU/L ในช่วงปีพุทธศักราช 2541 ในช่วงปี ที่ทำการศึกษาพบผู้ป่วยที่มีภาวะเอนไซม์อัลคาไลน์ฟอสฟາเตสในเลือดสูงเข้าเกณฑ์ 203 ราย โดย มี 163 รายที่สืบค้นการวินิจฉัยขั้นสุดท้ายได้ พบว่ามี 3 รายที่มีภาวะเอนไซม์อัลคาไลน์ฟอสฟາ-เตสในเลือดสูงจากยา (allopurinol 2 ราย และ diphenylhydantoin 1 ราย) ค่าเฉลี่ยของเอนไซม์ อัลคาไลน์ฟอสฟາเตสในเลือดของผู้ป่วยกลุ่มนี้เท่ากับ $4,023.0 \pm 3,493.6$ IU/L ภาวะเอนไซม์ อัลคาไลน์ฟอสฟາเตสในเลือดสูงจากยาพบได้ไม่น่าอย ค่าร้อยละสัมพัทธ์ของภาวะนี้ต่อภาวะ เอนไซม์อัลคาไลน์ฟอสฟາเตสในเลือดสูงจากยาโดยรวมเท่ากับ 1.47% และเมื่อเทียบกับการส่ง ตรวจระดับเอนไซม์อัลคาไลน์ฟอสฟາเตสทั้งหมดในช่วงดังกล่าวพบความชุกของภาวะที่ศึกษาเท่า กับ 1: 10,000

คำสำคัญ : ภาวะเอนไซม์อัลคาไลน์ฟอสฟາเตสในเลือดสูง, ฤทธิ์แทรกแซงจากยา,
ผู้ป่วยชาวไทย

INTRODUCTION

Alkaline phosphatase (ALP; EC 3.1.3.1) comprises a group of enzymes that catalyze the hydrolysis of phosphate esters in an alkaline environment, generating an organic radical and inorganic phosphate¹. An increase in serum ALP level is frequently associated with a variety of diseases. Such disorders as extrahepatic bile obstruction, intrahepatic cholestasis, infiltrative liver disease, hepatitis and drug induced disorder are mentioned¹⁻³. Unfortunately, the elevation of ALP less than three times the normal level is considered non specific and insufficient to provide a definite diagnosis¹⁻³.

In order to determine the prevalence of drug induced markedly elevated serum ALP among Thai hospitalized patients, a review was made of medical records of individuals in whom an ALP level was equal to or greater than 1,000 IU/L during a one-year period in a Thai tertiary hospital.

MATERIALS AND METHODS

This study was performed as a retrospective study. A retrospective case review was made on hospitalized patients who had an ALP level equal to or greater than 1,000 IU/L (Boehringer Manheim, normal 98-279 IU/L)

at the Department of Laboratory Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. This study focused on a one-year period, from January 1998 to December 1998. The review of the patients' medical records during this period included 203 hyperalkalinephosphatasemic cases with a conclusive diagnosis for further analysis. The data from the discharge summary of these patients were then recorded including their age as well as the final diagnosis. The cases without final diagnosis were excluded.

Descriptive statistics were used in analyzing the patient characteristics and laboratory parameters of each group. All the statistical analyses in this study were made using SPSS 7.0 for Windows Program.

RESULTS

During the one-year period, a total of 203 hospitalized patients with serum ALP levels over 1,000 IU/L were identified. Of these 203 cases, 163 had got the definitive diagnosis (Table 1). In interest, only 3 cases with diagnosis of drug induced hyperalkalinephosphatasemia were identified (allopurinol in 2 cases and diphenylhydantoin in 1 case). The average serum ALP in these cases was equal to $4,023.0 \pm 3,493.6$ IU/L (Table 2).

Table 1. Characteristics of included 163 subjects.

Parameters		Characteristics
Age (years)		
Range		21-93
Mean		52.3 ± 15.5
sex		
male		88
female		75

Table 2. Drug-induced hyperalkalinephosphatasemia in the series.

No.	sex	Age (years)	Drug	Serum ALP (IU/L)*	Serum bilirubin (mg %)**	Liver biopsy	Recovery after discontinuation
1	Female	53	Allopurinol	8,057	40.5	no	yes
2	Female	53	Allopurinol	2,014	20.4	no	yes
3	Male	50	Diphenylhydantoin	1,998	19.7	no	yes

* normal value 98-279 IU/L

** normal value 0-1 mg%

DISCUSSION

A number of diseases are related to the elevation of serum ALP¹, therefore, a study of the etiologies of high serum ALP can be useful in diagnosis. According to a recent report, drug induced toxicity is rarely a cause of hyperalkalinephosphatasemia in the hospitalized patients³. The relative percentage of drug-induced hyperalkalinephosphatasemia was equal to 1.47 %. Comparing to the total ALP tests performed in the setting in the study period, the low prevalence as 1: 10,000 was observed.

However, each case of drug-induced hyperalkalinephosphatasemia seems to be severe and was overlooked. In our series, a

case with serum ALP as high as 8,057 IU/L was identified. However, on follow up, all patients' serum ALP returned to normal limit within a few months after discontinuation of the drug administration. Indeed, hepatocellular necrosis and a mixed hepatocellular and cholestatic pattern have been previously reported with allopurinol therapy⁴. The mechanism of hepatic injury seems to be that of hypersensitivity with a relatively fixed induction period, development of fever with rash and peripheral eosinophilia as well as the findings of tissue eosinophilia and noncaseating granuloma on liver biopsy. Likewise, the patterns of liver damage have also been described in cases with phenytoin toxicity⁵.

REFERENCES

1. Reichling JJ, Kaplan MM. Clinical use of serum enzymes in liver diseases. *Dig Dis Sci* 1988; 33: 1601-1614.
2. McIntyre N, Rosalki S. Biochemical investigations in the management of liver disease. In: McIntyre N, editor. Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press, 1991: 293-309.
3. Wiwanitkit V. High serum alkaline phosphatase levels, a study in 181 Thai hospitalized adult patients. *BMC Fam Pract* 2001;2:2.
4. Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG. Allopurinol hepatotoxicity. Report of two cases and review of the literature. *Ann Intern Med* 1981; 95: 588-590.
5. Mulluck FG, Ishak KG. Hepatic injury associated with diphenylhydantoin therapy: a clinicopathologic study of 20 cases. *Am J Clin Pathol* 1980; 74: 442-452.